SPHK1 and chronic myelogenous leukemia, BCR-ABL1 positive: Other studies revealed that SPHK1 overexpression in CML imatinib-resistant cells is regulated by signaling through PI3K, AKT2 and mTOR, with AKT playing a major role in the modulation of this resistance (84).